#Australia #Ponte Vedra #presbyopia #Orasis #BESKA

Orasis Pharmaceuticals Submits New Drug Application for BESKA in Australia

Orasis Pharmaceuticals, in partnership with Aspen Australia, has made significant strides in the pharmaceutical landscape by submitting a new drug application (NDA) for their product, BESKA (pilocarpine hydrochloride ophthalmic solution), designed to address presbyopia in adults. This submission is particularly notable as it marks the first regulatory move outside of the U.S., where the drug is known as QLOSI.

The NDA was presented to the Therapeutic Goods Administration (TGA) in Australia and is supported by compelling data collected from two pivotal Phase 3 clinical trials, designated NEAR-1 and NEAR-2. These studies collectively evaluated the efficacy, safety, and tolerability of BESKA among more than 600 adult participants suffering from presbyopia, a common age-related condition characterized by the gradual loss of the ability to focus on near objects. Both trials not only met their primary endpoints but also achieved key secondary goals, resulting in a statistically significant improvement in distance-corrected near visual acuity (DCNVA) without any perceptible loss in distance vision.

In the trials, it was reported that the adverse effects were minimal, with rates for the most common side effects, headache and instillation site pain, recorded at 6.8% and 5.8%, respectively, demonstrating the safety profile of BESKA. The CEO of Orasis Pharmaceuticals, Elad Kedar, expressed enthusiasm about this milestone and emphasized the commitment to increasing the availability of effective treatments for presbyopia in markets beyond the U.S. He stated, "Aspen's experienced team is ready to collaborate with local regulators to secure the necessary approval and subsequently commercialize BESKA in Australia. This will provide eye care professionals with a flexible alternative to conventional reading glasses for their presbyopia patients."

Aspen's Regional Chief Executive for Asia Pacific, Trevor Ziman, shared similar sentiments, recognizing the NDA's submission as an essential addition to their existing medicine portfolio aimed at enhancing visual health and the quality of life for communities in Australia.

Understanding Presbyopia

Presbyopia is a condition linked to aging that generally affects individuals over the age of 40. It arises due to the hardening of the crystalline lens of the eye, leading to blurred vision when attempting to focus on nearby objects. As per statistics, nearly two billion people globally, including approximately 128 million in the U.S., are affected by presbyopia. For individuals diagnosed, daily activities, such as reading or navigating their smartphones, can become challenging. Effective solutions are limited, often proving cumbersome or requiring invasive procedures, thus highlighting an unmet demand for effective treatments.

The Innovative Approach of BESKA

BESKA is a novel, preservative-free eye drop formulated to enhance near visual acuity by adjusting pupil size, thereby creating a "pinhole effect" that increases the depth of field. This mechanism allows users to focus on nearby objects more effectively without adversely impacting distance vision. With the lowest effective concentration of pilocarpine available in eye drops, BESKA promises both efficacy and comfort for users. The TGA's review process will be pivotal in determining the future of this product in Australia.

Orasis Pharmaceuticals is an innovative ophthalmic company dedicated to reshaping vision possibilities. As they gear up for the anticipated approval and launch of BESKA next year, efforts to establish beneficial partnerships and streamline the launch will be essential in translating clinical success into market availability.

This potential release underscores a major step forward in the treatments available for presbyopia, with the hopes of benefiting millions worldwide who are grappling with the challenges posed by diminishing near vision. Improving visual acuity with minimal side effects could transform everyday experiences for countless individuals, making it an exciting development in the field of eye care.